New study tracks sorafenib safety in Hard-to-Treat thyroid cancer
NCT ID NCT02185560
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study monitors 453 patients with advanced thyroid cancer that cannot be removed by surgery and does not respond to radioactive iodine. All patients are taking the drug sorafenib (Nexavar) as part of their normal care. Researchers are tracking side effects and how long patients live or stay on treatment over 9 to 24 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sorafenib (Nexavar)
What this could lead to
If successful, this study will confirm the safety and real-world effectiveness of sorafenib for advanced thyroid cancer, supporting its continued use.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be limited by short follow-up and lack of a comparison group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Multiple Locations, Japan